Skip to main content
spacbrain

Orchestra BioMed Holdings

Closed (deSPAC)

Health Care · biomedical therapeutics and medical device development

What it is
BioMed Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies
What it’s doing now
Merging with Health Sciences Acquisitions Corp 2 (HSAQ) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

BioMed Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy™ (CNT™) for the treatment of hypertension, a significant risk factor for death worldwide, and Virtue ® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo Corporation, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com , and follow us on LinkedIn and Twitter. References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of th

Source: S-4/A, accession 0001213900-22-079265

What the company says about itself

Web research — not audited

Orchestra BioMed is a company that brings medical innovations to life by accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Their partnership-enabled business model focuses on forging strategic collaborations to drive successful global commercialization of products they develop.

Markets:
medical devices | therapeutic device development
Products:
Atrioventricular Interval Modulation Therapy (AVIM Therapy) | Virtue® Sirolimus AngioInfusion™ Balloon (SAB)

Source: https://www.orchestrabiomed.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Orchestra BioMed Holdings is merging with Health Sciences Acquisitions Corp 2 (HSAQ) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $25M · unsourced

Structure per SEC accession(s) 0001213900-22-045485. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Orchestra BioMed Holdings going public?

Orchestra BioMed Holdings has an approved merger with the SPAC Health Sciences Acquisitions Corp 2 (HSAQ). Deal status: Closed (deSPAC).

Does Orchestra BioMed Holdings have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals